{"nctId":"NCT01778049","briefTitle":"Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes","startDateStruct":{"date":"2013-01"},"conditions":["Diabetes Mellitus, Type 2"],"count":708,"armGroups":[{"label":"Empagliflozin 10 mg dose","type":"EXPERIMENTAL","interventionNames":["Drug: BI 10773"]},{"label":"Placebo add on 10 mg dose","type":"EXPERIMENTAL","interventionNames":["Drug: BI 10773 / BI 1356 Placebo","Drug: BI 10773"]},{"label":"Empagliflozin/Linagliptin 25/5 mg Dose","type":"EXPERIMENTAL","interventionNames":["Drug: BI 10773 / BI 1356","Drug: BI 10773 Placebo"]},{"label":"Empagliflozin/Linagliptin 10/5 mg Dose.","type":"EXPERIMENTAL","interventionNames":["Drug: BI 10773 / BI 1356 Placebo","Drug: BI 10773"]},{"label":"Empagliflozin/Linagliptin 10/5 mg Dose","type":"EXPERIMENTAL","interventionNames":["Drug: BI 10773 Placebo","Drug: BI 10773 / BI 1356"]},{"label":"Empagliflozin 25 mg dose","type":"EXPERIMENTAL","interventionNames":["Drug: BI 10773"]},{"label":"Empagliflozin/Linagliptin 25/5 mg Dose.","type":"EXPERIMENTAL","interventionNames":["Drug: BI 10773","Drug: BI 10773 / BI 1356 Placebo"]},{"label":"Placebo add on 25 mg dose","type":"EXPERIMENTAL","interventionNames":["Drug: BI 10773","Drug: BI 10773 / BI 1356 Placebo"]}],"interventions":[{"name":"BI 10773","otherNames":[]},{"name":"BI 10773 Placebo","otherNames":[]},{"name":"BI 10773 / BI 1356","otherNames":[]},{"name":"BI 10773","otherNames":[]},{"name":"BI 10773 / BI 1356","otherNames":[]},{"name":"BI 10773 / BI 1356 Placebo","otherNames":[]},{"name":"BI 10773","otherNames":[]},{"name":"BI 10773","otherNames":[]},{"name":"BI 10773","otherNames":[]},{"name":"BI 10773 / BI 1356 Placebo","otherNames":[]},{"name":"BI 10773 Placebo","otherNames":[]},{"name":"BI 10773 / BI 1356 Placebo","otherNames":[]},{"name":"BI 10773","otherNames":[]},{"name":"BI 10773 / BI 1356 Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Signed and dated ICF (Informed Consent Form)\n2. Male or female on diet and exercise regime and on stable background metformin \\> or equal to 1500 mg or maximun dose according to local label\n3. HBA1c (Glicoslated Hemoglobin) \\> or equal to 8% and \\< or equal to 10.5 % at Visit 1\n4. HbA1c \\> or equal to 7 and \\< or equal to 10.5 at Visit 4\n5. Age \\> or equal to 18 years\n6. BMI (Body Mass Index) \\< or equal to 45\n\nExclusion criteria:\n\n1. Uncontrolled hyperglycemia during open label period and placebo add on \"run-in\" period\n2. Use of any other antidiabetic\n3. Renal function below 60 ml/min/1.73 m2\n4. Antiobesity drugs or aggresive diets\n5. Gastorintestinal surgeries\n6. Current systemic steroids or uncontrolled endocrine disorders other than Diabetes Type 2\n7. Acute coronary syndrome and stroke within 3 months of informed consent\n8. Known allergies to DPP-IV (Dypeptidil Peptidase IV) or SGLT-2 (Sodium Glucose Transporter 2) inhibitors","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline of HbA1c After 24 Weeks of Treatment.","description":"Change from baseline in Glycated haemoglobin (HbA1c) \\[%\\] after 24 weeks of treatment with double-blind trial medication, i.e. HbA1c change from baseline at Week 24. The term \"baseline\" was not used to refer to measurements prior to the administration of open-label medication. Such measurements were referred to as \"pre-treatment\". Analyses of change from pre-treatment used the last value before first administration of open-label medication as point of reference.\n\nObserved Case (OC): This method analyse only available data that were observed while patients were on treatment, i.e., excluding the missing data. All values measured after rescue medication taken were set to missing. Full Analysis Set (FAS): Includes all patients in the Treated set who had a baseline HbA1c assessment and at least 1 on-treatment HbA1c assessment during the double-blind part of the trial.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.53","spread":"0.07"},{"groupId":"OG001","value":"-0.21","spread":"0.07"},{"groupId":"OG002","value":"-0.58","spread":"0.07"},{"groupId":"OG003","value":"-0.10","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"Fasting Plasma Glucose (FPG) Change From Baseline at 24 Weeks.","description":"Change from baseline FPG (mmol/L) after 24 weeks of treatment with double-blind trial medication, i.e. FPG change from baseline at Week 24.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.44","spread":"0.18"},{"groupId":"OG001","value":"0.21","spread":"0.18"},{"groupId":"OG002","value":"-0.68","spread":"0.15"},{"groupId":"OG003","value":"-0.24","spread":"0.15"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":352},"commonTop":["Urinary tract infection","Lipase increased","Nasopharyngitis"]}}}